ULTRAVATE 0.05 %
HALOBETASOL PROPIONATE : 0.05 % · DIN 01962701 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is ULTRAVATE?
ULTRAVATE 0.05 % contains HALOBETASOL PROPIONATE : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 01962701, held by BAUSCH HEALTH, CANADA INC., supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 15-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ULTRAVATE used for?
ULTRAVATE (halobetasol propionate) is a high to super-high potency topical corticosteroid indicated for corticosteroid-responsive dermatoses and the relief of inflammatory manifestations of resistant or severe psoriasis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01962701 |
|---|---|
| Brand name | ULTRAVATE |
| Generic / active ingredient | HALOBETASOL PROPIONATE : 0.05 % |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 0.05 % |
| Dosage form | CREAM |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D07AC21 ULOBETASOL |
| AHFS class | 84:06.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Oct-2019 |
| Original market date | 1993-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
50 g aluminum tubes
What can be used instead?
Other Canadian products sharing ATC code D07AC21 ULOBETASOL. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRYHALI | 0.01 % | LOTION | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02506262 |
| ULTRAVATE | 0.05 % | OINTMENT | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 01962728 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.